Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in combination with either pembrolizumab or cetuximab as a strategy to overcome tumor ...
Purple Biotech reports positive trial results for CM24 and NT219, advancing toward biomarker-driven studies and expanding its oncology pipeline. Purple Biotech Ltd. announced positive results from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results